The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...

Sen. Bill Cassidy, whose “yes” vote advanced Kennedy’s nomination as health secretary, said Kennedy promised to maintain ACIP ...

Analysts said the move comes amid rising trade tensions with the U.S. and as Illumina faces stiff competition in China’s ...